R. Jeselsohn

Abstract PS2-02-07: Impact of BRCA homozygous copy loss on clinical outcomes of patients (pts) with metastatic breast cancer (MBC) treated with PARP inhibitors (PARPi)
20260 citationsauthor #12
The CHI3L1-neutrophil axis drives immune suppression and breast cancer metastatic dissemination.
20260 citationsauthor #20
Androgen receptor expression and immune characteristics of HER2-low metastatic triple-negative breast cancer.
20260 citationsauthor #11
Abstract PD9-07: The Genomic, Transcriptomic, and Immune Hallmarks of Metastatic Lobular Breast Cancer
20260 citationsauthor #17
PS5-09-15: ERADICATE: A phase Ib/II study of elacestrant plus trastuzumab deruxtecan in patients with CDK4/6 inhibitor and endocrine-resistant HR+/HER2-low or HER2-ultralow metastatic breast cancer
20260 citationsauthor #10
Abstract PD2-09: Convergent genomic evolution from early to lethal HR+/HER2- metastatic breast cancer
20260 citationsauthor #19
Abstract PS2-07-16: Clinicogenomic characterization and ctDNA detection of ESR1 fusion positive metastatic breast cancer
20260 citationsauthor #19
Abstract 1172: An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer
20250 citationsauthor #21
Efficacy, safety, and predictive biomarkers of neoadjuvant nab-paclitaxel and pembrolizumab in hormone receptor-positive breast cancer: A randomized pilot trial
20250 citationsauthor #14
PROFET Predicts Continuous Gene Expression Dynamics from scRNA-seq Data to Elucidate Heterogeneity of Cancer Treatment Responses
20251 citationsauthor #14
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)
20258 citationsauthor #20
Imlunestrant a next-generation oral SERD overcomes ESR1 mutant resistance in estrogen receptor–positive breast cancer
20257 citationsauthor #16
Use of baseline plasma circulating tumor DNA (ctDNA) to predict duration of endocrine therapy (ET) and CDK4/6 inhibitor (CDK4/6i) therapy (tx) and to analyze intrinsic vs acquired endocrine resistance.
20251 citationsauthor #19
Abstract P1-02-20: Visceral adiposity is associated with survival and distinct gene expression patterns in HER2-enriched subtype tumors
20250 citationsauthor #8
Abstract 1181: Combined inhibition of KAT6 and menin reverses estrogen receptor-driven gene expression programs in breast cancer
20250 citationsauthor #5
Abstract P2-01-20: Impact of Exercise on Immune Biomarkers in Benign Breast Tissue from Women with High Mammographic Breast Density (MBD)
20250 citationsauthor #11
Abstract PS9-08: Ultra-sensitive detection of circulating tumor DNA (ctDNA) in patients (pts) undergoing neoadjuvant endocrine therapy for hormone receptor-positive (HR+) early breast cancer (BC)
20250 citationsauthor #12
Super-resolution microscopy reveals distinct epigenetic states regulated by estrogen receptor activity
20250 citationsauthor #9
Estrogen receptor (ER) expression on circulating tumor cells (CTCs) and cell free DNA (cfDNA) mutational landscape in the PACE randomized phase II study.
20250 citationsauthor #4
Tamoxifen induces PI3K activation in uterine cancer
20254 citationsauthor #34
Abstract 1319: Luminal reprogramming, druggable mitogenic pathway activation, and rare outgrowth of occult basal cancers define ER loss in HR+/HER2- MBC
20250 citationsauthor #11
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study.
20250 citationsauthor #4
Abstract P1-01-26: Genomic profiling of ctDNA & assoc. w/ efficacy in patients from the postMONARCH trial of abemaciclib + fulvestrant vs placebo + fulvestrant for HR+, HER2-, advanced breast cancer following progression on a prior CDK4/6i plus endocrine therapy
20250 citationsauthor #3
Mystery of tamoxifen-associated uterine cancer uncovered
20250 citationsauthor #3
TRLS-09 CEREBROSPINAL FLUID (CSF) AND PLASMA CIRCULATING TUMOR DNA (CTDNA) FOR MOLECULAR PROFILING AND MONITORING OF TREATMENT RESPONSE IN A PHASE II TRIAL OF PAXALISIB FOR HER2-POSITIVE (HER2+) BREAST CANCER BRAIN METASTASES (BCBM)
20250 citationsauthor #16
Abstract P2-07-25: Thymidine kinase activity as a prognostic and predictive biomarker in the Phase II PACE trial of CDK4/6 inhibition beyond progression
20251 citationsauthor #22
Super-resolution microscopy reveals distinct epigenetic states regulated by estrogen receptor activity
20250 citationsauthor #10
MUC1-C dependency in drug resistant HR+/HER2− breast cancer identifies a new target for antibody-drug conjugate treatment
20256 citationsauthor #19
Abstract PS2-09: Liquid biopsy DNADX assay in advanced ER+/HER2-negative breast cancer after progression on CDK4/6 and aromatase inhibitors: a correlative analysis from the PACE phase II randomized trial
20250 citationsauthor #34
Abstract P2-03-20: Correlation of cell cycle arrest and intrinsic subtype with pathologic nodal status after neoadjuvant endocrine therapy – results from the Palbociclib and Endocrine therapy for Lobular breast cancer Preoperative Study
20250 citationsauthor #22
Abstract PS18-06: Primary results and the transcriptomic analysis of PELOPS, a randomized phase II study of neoadjuvant palbociclib with or without endocrine therapy for breast cancer patients with invasive lobular carcinoma or invasive ductal carcinoma
20250 citationsauthor #1
PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degraders for Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
20257 citationsauthor #2
Abstract P4-03-20: Molecular characterization of estrogen receptor (ER)+/HER2- breast cancer unveils a biologically and clinically distinct entity with ERBB2 hemizygous deletion (ERBB2del)
20250 citationsauthor #17
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
20250 citationsauthor #18
Combined inhibition of KAT6A/B and Menin reverses estrogen receptor-driven gene expression programs in breast cancer
20255 citationsauthor #10
Abstract PS14-07: Spatial transcriptomics of matched breast cancer brain metastases and primary tumors identifies a brain-specific immune-suppressive transcriptional program
20250 citationsauthor #7
Abstract P4-08-01: pionERA Breast Cancer: Phase 3 study of first-line giredestrant vs fulvestrant, + a CDK4/6 inhibitor, in patients with estrogen receptor+, HER2- locally advanced/metastatic breast cancer with resistance to prior adjuvant endocrine therapy
20250 citationsauthor #2
A Phase II Study of Abemaciclib for Patients with Retinoblastoma-Positive, Metastatic Triple-Negative Breast Cancer
20255 citationsauthor #9
Cellular reprogramming during anti-PD-1 and chemotherapy treatment in early-stage primary hormone receptor-positive breast cancer
20252 citationsauthor #17
Abstract P5-05-04: Final results of a phase II trial evaluating paxalisib with trastuzumab for patients (pts) with HER2 positive metastatic breast cancer with active brain metastases
20250 citationsauthor #13
Abstract 7225: The secreted cytokine Chitinase 3-like-1 promotes breast cancer metastasis
20250 citationsauthor #11
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
202435 citationsauthor #6
Abstract PO2-27-12: Genomic determinants of benefit to nivolumab (NIVO) plus low dose ipilimumab (IPI) among patients (pts) with hypermutated HER2-negative metastatic breast cancer (MBC): results of NIMBUS trial
20240 citationsauthor #17
Estrogen Receptor Mutations as Novel Targets for Immunotherapy in Metastatic Estrogen Receptor–positive Breast Cancer
202411 citationsauthor #12
Abstract PS08-09: Impact of HER2 expression dynamics on the real-world activity of trastuzumab deruxtecan for metastatic breast cancer (RELIEVE)
20246 citationsauthor #17
Abstract 3707: Characterization of estrogen receptor expression on CTCs during CDK4/6i treatment in HR+/HER2- metastatic breast cancer: Results from the PACE phase II study
20242 citationsauthor #4
Abstract PO3-05-08: Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer
20246 citationsauthor #10
Somatic Activating ESR1 Mutation in an Aggressive Prolactinoma.
20242 citationsauthor #10
1407 Identification of tumor-intrinsic and extrinsic mechanisms of T cell exclusion in estrogen receptor-positive breast cancer through bulk and single-cell transcriptome and spatial analysis
20240 citationsauthor #11
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
202448 citationsauthor #6
Estrogen receptor alpha mutations, truncations, heterodimers, and therapies.
202413 citationsauthor #3
Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort
20246 citationsauthor #2
An estrogen receptor signaling transcriptional program linked to immune evasion in human hormone receptor-positive breast cancer
20241 citationsauthor #21
Abstract 109: Identification of tumor-intrinsic and extrinsic mechanisms of T cell exclusion in estrogen receptor-positive (ER+) breast cancer through integration of bulk and single-cell transcriptome and spatial analysis
20240 citationsauthor #11
Abstract GS03-09: Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers
20244 citationsauthor #21
Abstract PR012: KAT6A/B and Menin-MLL complexes coordinately regulate estrogen receptor-driven gene expression programs in breast cancer
20241 citationsauthor #4
Abstract PS12-02: Exploration of ctDNA Dynamics in the PACE Trial: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab for HR+/HER2- Metastatic Breast Cancer
20240 citationsauthor #1
Abstract PO3-01-09: Results of a prospective observational study evaluating the impact of the Prosigna assay on neoadjuvant treatment decision-making in patients with early-stage HR+/HER2- breast cancer
20241 citationsauthor #14
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study
202428 citationsauthor #3
Abstract PS12-06: A phase 2 study of abemaciclib monotherapy for patients with retinoblastoma-positive (Rb+), triple-negative metastatic breast cancer
20241 citationsauthor #10
Abstract PS15-09: Imlunestrant monotherapy and in combination with abemaciclib, with or without an aromatase inhibitor, in estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced breast cancer (aBC): updated results from the EMBER study
20243 citationsauthor #3
Osteopontin is a therapeutic target that drives breast cancer recurrence
202421 citationsauthor #18
Abstract A025: KAT6A/B and Menin-MLL complexes coordinately regulate estrogen receptor-driven gene expression programs in breast cancer
20240 citationsauthor #4
Abstract PO5-26-07: Surgery for Invasive Lobular Carcinoma: A Patient Experience Survey from the Lobular Breast Cancer Alliance
20240 citationsauthor #5
Abstract PO3-04-13: SUMIT-ELA: Phase 1b/2 combination of cyclin-dependent kinase 7 inhibitor (CDK7i) samuraciclib and selective estrogen receptor degrader (SERD) elacestrant in advanced hormone receptor positive (HR+) breast cancer after CDK4/6i
20242 citationsauthor #11
Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer
202422 citationsauthor #31
Pure estrogen receptor antagonists potentiate capecitabine activity in ESR1-mutant breast cancer
20244 citationsauthor #18
Mathematical Modeling Identifies Optimum Palbociclib-fulvestrant Dose Administration Schedules for the Treatment of Patients with Estrogen Receptor–positive Breast Cancer
20235 citationsauthor #9
Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2– mBC): Prevalence, biomarker characteristics, and outcomes.
20230 citationsauthor #1
Abstract GS3-07: GS3-07 Clonal evolution and mechanisms of acquired resistance to CDK4/6 inhibitors in ER-wild type and ER-mutant breast cancer
20233 citationsauthor #14
HATS off to KAT6A/B inhibitors: A new way to target estrogen-receptor-positive breast cancer.
20234 citationsauthor #1
Corrigendum: ESR1 fusions and therapeutic resistance in metastatic breast cancer
20231 citationsauthor #2
Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
20232 citationsauthor #18
Abstract GS3-03: GS3-03 ARV-471, a PROTAC® estrogen receptor (ER) degrader in advanced ER-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer: phase 2 expansion (VERITAC) of a phase 1/2 study
202333 citationsauthor #11
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
202347 citationsauthor #7
The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer.
202313 citationsauthor #3
Endocrine Therapy Synergizes with SMAC Mimetics to Potentiate Antigen Presentation and Tumor Regression in Hormone Receptor–Positive Breast Cancer
20239 citationsauthor #41
ESR1 fusions and therapeutic resistance in metastatic breast cancer
202331 citationsauthor #2
Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
202347 citationsauthor #18
Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer
202352 citationsauthor #18
High FOXA1 levels induce ER transcriptional reprogramming, a pro-metastatic secretome, and metastasis in endocrine-resistant breast cancer.
202315 citationsauthor #19
Abstract HER2-05: HER2-05 Comprehensive genomic characterization of HER2-low breast cancer
20232 citationsauthor #17
The dilemma of selecting a first line CDK4/6 inhibitor for hormone receptor-positive/HER2-negative metastatic breast cancer
202339 citationsauthor #4
Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib
20230 citationsauthor #18
Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy
20233 citationsauthor #17
A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER.
202230 citationsauthor #2
Author Correction: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers
20220 citationsauthor #21
Longitudinal circulating tumor DNA (ctDNA) whole-exome sequencing (WES) in the phase Ib/II trial of palbociclib and bazedoxifene reveals genomic dynamics and clonal evolution with the acquisition of treatment resistance in hormone receptor-positive, HER2-negative (HR+ HER2-), advanced breast cancer
20221 citationsauthor #15
Abstract GS3-10: Study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in combination with fulvestrant in patients with advanced hormone receptor positive HER2 negative breast cancer (HR+BC)
20225 citationsauthor #14
Abstract GS2-09: Tamoxifen instigates uterine cancer development by activating PI3K signaling and supersedes PIK3CA driver mutations
20221 citationsauthor #29
ESR1 activating mutations: From structure to clinical application.
202243 citationsauthor #5
Auricular Acupuncture During Chemotherapy Infusion in Breast Cancer Patients: A Feasibility Study
20224 citationsauthor #8
Abstract 3984: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers
20220 citationsauthor #18
Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.
20224 citationsauthor #2
Abstract PD1-05: Targeting the FRA1-dependent transcriptional nexus in high FOXA1-driven endocrine-resistant and metastatic breast cancer
20220 citationsauthor #8
Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status
202239 citationsauthor #4
Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer.
2022179 citationsauthor #4
Temporal and spatial topography of cell proliferation in cancer
202216 citationsauthor #12
A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer
202215 citationsauthor #25
Abstract P1-04-13: Generation and validation of an estrogen receptor signaling (ERS) gene panel that inversely correlates with antigen presentation and T cell infiltration and activity in hormone receptor positive (HR+) breast cancer
20220 citationsauthor #7

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT